The U.S. House of Representatives on Monday overwhelmingly passed the bipartisan bill, which targets WuXi AppTec, WuXi Biologics and other Chinese biotech companies as potential national security risks.
Tag Archive for: WuXi Biologics
With the potential passage of the BIOSECURE Act looming, WuXi Biologics reported a 24% drop in net profit in the first half of 2024.
The Biden administration said Thursday it had removed Wuxi Biologics, a company that makes ingredients for AstraZeneca’s COVID-19 vaccine, and about two dozen other Chinese entities from a so-called unverified list that forces U.S. suppliers to perform greater due diligence before shipping to them.
The U.S. Food and Drug Administration on Friday extended for the second time its review of Amicus Therapeutics Inc.’s experimental combination therapy to treat a muscle disorder called Pompe disease.
Wuxi Biologics, a Chinese company that makes ingredients for AstraZeneca’s COVID-19 vaccine, may be a step closer to being taken off a U.S. trade list that it landed on five months ago, wiping HK$77 billion ($9.9 billion) off its market value at the time.